Recombinant 2019-nCov Nucleocapsid Protein
Referência PR-nCoV-1
Tamanho : 100ug
Marca : Novatein Biosciences
Contactar o distribuidor local :
Telefone : +1 850 650 7790
Recombinant 2019-nCov Nucleocapsid Protein
PR-nCoV-1
Data sheet
| Background | N-protein, being one of the predominantly expressed proteins at the early stage of SARS-CoV infection, against which a strong antibody response is initiated by the host; has been proposed to be an attractive diagnostic tool.In serum of SARS-CoV patients, the N-protein has been detected as early as day 1 of infection by ELISA using monoclonal antibodies against it. Furthermore, a comparative study to detect SARS-CoV specific IgG, SARS-CoV RNA, and the N-protein during early stages of infection has demonstrated that detection efficiency of the N-protein is significantly higher than the other two markers. N-protein has been one of the top target for development of IgM ELISA for diagnostic purpose. N-protein has also been tested in its use as a protective vaccine against SARS-CoV infection. So it could be a potential vaccine candidate in the effort to develop an efficient vaccine against 2019-nCov/COVID. |
| Purity | 95%，by SDS-PAGE under reducing conditions. |
| Expression host | E.coli |
| Protein formulation | Lyophilized from 0.22 μm filtered solution in 1x PBS, pH7.4. Contact us for customized product form or formulation. |
| Stability / Shelf Life | The product should be stored at lyophilized state at -20 weeks, 2 months, -20 months, -70 kDa, and the actual MW is about 50 kDa in SDS-PAGE under reducing conditions |
More info
nCoV, or COVID/NCP. Hence major attention has been focused on characterization of this protein. Independent studies conducted by several laboratories have elucidated significant insight into the primary function of this protein, which is to encapsidate the viral genome. The COVID N protein share high homology with the SARS-Cov of infection by ELISA using monoclonal antibodies against it. Furthermore, a comparative study to detect SARS-CoV specific IgG, SARS-CoV RNA, and the N-protein during early stages of infection has demonstrated that detection efficiency of the N-protein is significantly higher than the other two markers. N-protein has been one of the top target for development of IgM ELISA for diagnostic purpose.
N-protein has also been tested in its use as a protective vaccine against SARS-CoV infection. So it could be a potential vaccine candidate in the effort to develop an efficient vaccine against 2019-nCov/COVID.-recombinant-2019-ncov-spikerbdhfc-protein.html">SARS-CoV2 RBD
class="page-product-heading">Download